Although cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) remain the most clinically valuable tumor biomarkers for EOC diagnosis, their diagnostic accuracy requires further improvement. This evidence concerns the gene WFDC2 and neoplasm.